Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04623242 · ClinicalTrials.gov registry record · Phase 2
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 194
- Enrollment target
NCT04623242 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 194 participants.
The verdict
NCT04623242, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 194 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive impairment and improves disease-related biomarkers. This is an analysis study for an MPRP: DIAN-TU-001 Master NCT01760005
Interventions
- DRUG Gantenerumab
- DRUG Solanezumab
- DRUG Matching Placebo (Gantenerumab)
- DRUG Matching Placebo (Solanezumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2012-12 |
| Est. Completion | 2020-03-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04623242
The ClinicalTrials.gov registry entry for NCT04623242 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Gantenerumab is the first listed.
NCT04623242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04623242 about?
NCT04623242 is a clinical study titled "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.". The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive impairmen...
What is the current status of trial NCT04623242?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 194 participants. The study started on 2012-12. Estimated completion is 2020-03-06.
What interventions are being tested in trial NCT04623242?
The interventions under investigation include: Gantenerumab (DRUG), Solanezumab (DRUG), Matching Placebo (Gantenerumab) (DRUG), Matching Placebo (Solanezumab) (DRUG).
Who is sponsoring clinical trial NCT04623242?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.